scholarly article | Q13442814 |
P50 | author | Jane Anderson | Q21544772 |
Andrew N Phillips | Q87677848 | ||
Philippa Easterbrook | Q90656517 | ||
Mark Bower | Q41594532 | ||
Caroline Sabin | Q42249738 | ||
Kholoud Porter | Q53124393 | ||
Deenan Pillay | Q57899870 | ||
Chloe Orkin | Q87418404 | ||
P2093 | author name string | John Walsh | |
Martin Fisher | |||
Brian Gazzard | |||
Loveleen Bansi | |||
Richard Gilson | |||
Iain Reeves | |||
Margaret Johnson | |||
Clifford Leen | |||
Mark Gompels | |||
Teresa Hill | |||
Achim Schwenk | |||
UK CHIC Steering Committee | |||
P2860 | cites work | HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts | Q33280133 |
Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults | Q33925343 | ||
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy | Q34093851 | ||
Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy | Q34403321 | ||
Immune reconstitution after highly active anti-retroviral treatment of HIV infection. | Q34483191 | ||
Trends in cancer risk among people with AIDS in the United States 1980-2002. | Q34569368 | ||
Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma | Q35174152 | ||
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). | Q36653838 | ||
Indicator disease-guided testing for HIV--the next step for Europe? | Q37192570 | ||
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy | Q38491355 | ||
Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study | Q38499506 | ||
Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study | Q38638675 | ||
Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy | Q40744123 | ||
Reduced incidence of Kaposi's sarcoma and of systemic non-hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. | Q45179311 | ||
Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy | Q45710801 | ||
Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival | Q46164918 | ||
Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma | Q49273653 | ||
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel | Q50105738 | ||
Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy | Q56528095 | ||
The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study | Q57181218 | ||
Incidence of AIDS-Defining Cancers After AIDS Diagnosis Among People with AIDS in Italy, 1986–1998 | Q58281812 | ||
Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion | Q59119701 | ||
Immune deficiency and risk for malignancy among persons with AIDS | Q73224505 | ||
Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy | Q73794336 | ||
P433 | issue | 6 | |
P921 | main subject | HIV | Q15787 |
P304 | page(s) | 875-880 | |
P577 | publication date | 2009-03-31 | |
P1433 | published in | Haematologica | Q5638209 |
P1476 | title | CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. | |
P478 | volume | 94 |
Q50101286 | A prospective study of serum microbial translocation biomarkers and risk of AIDS-related non-Hodgkin lymphoma |
Q38029093 | A review of the role of lymphoma markers and occupational and environmental exposures |
Q37684247 | An AIDS-defining neoplasm in a 30-year-old man on highly active antiretroviral therapy: a forgotten diagnosis? |
Q40250347 | Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada |
Q64128653 | Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study |
Q45358998 | Blood Epstein-Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma |
Q34661370 | Cancer biomarkers in HIV patients |
Q36102589 | Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000-2010 |
Q33863292 | Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy |
Q47266595 | Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. |
Q35112218 | Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes |
Q34498993 | Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution |
Q35830555 | Effects of long-term use of antiretroviral therapy on the prevalence of oral Epstein-Barr virus |
Q42719779 | Extranodal lymphoma masquerading as carcinoma of the breast in an HIV-positive male patient |
Q40043098 | Fever and generalised lymphadenopathy in an HIV-positive patient: a diagnostic challenge. |
Q46245165 | HIV-1 Tat protein induces DNA damage in human peripheral blood B-lymphocytes via mitochondrial ROS production. |
Q56112360 | HIV-related lymphoma |
Q37567836 | Immunotherapy for HIV-associated non-Hodgkin's lymphoma. |
Q41990454 | Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens |
Q92073643 | Non-Hodgkin lymphoma in people with HIV |
Q41101979 | PAX5-expressing ALK-negative anaplastic large cell lymphoma with extensive extranodal and nodal involvement |
Q40927354 | Remission of human immunodeficiency virus-related lymphoma in association with immune reconstitution on anti-retroviral therapy, without chemotherapy |
Q44314941 | Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy |
Q28081273 | Spontaneous Regression of Refractory Diffuse Large B-Cell Lymphoma with Improvement in Immune Status with ART in a Patient with HIV: A Case Report and Literature Review |
Q37106782 | Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. |
Q38615024 | The Effect of Antiretroviral Combination Treatment on Epstein-Barr Virus (EBV) Genome Load in HIV-Infected Patients |
Q95289784 | The Role of Microbial Translocation and Immune Activation in AIDS-Associated Non-Hodgkin Lymphoma Pathogenesis: What Have We Learned? |
Q38210131 | Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG). |